{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:43:36Z","timestamp":1786221816087,"version":"build-2736575974"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jns.2026.126097","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:01:23Z","timestamp":1783983683000},"page":"126097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["FcRn inhibitors in the treatment of CIDP"],"prefix":"10.1016","volume":"489","author":[{"given":"Alexander H.","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jns.2026.126097_bb0005","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2021","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126097_bb0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force\u2014second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.jns.2026.126097_bb0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126097_bb0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awab422","article-title":"Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy","volume":"145","author":"Cornblath","year":"2022","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126097_bb0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/jns.12573","article-title":"Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial","volume":"28","author":"Bril","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0035","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews","volume":"2017","author":"Oaklander","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.jns.2026.126097_bb0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","article-title":"Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice","volume":"15","author":"Gorson","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.jns.2026.126097_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.126097_bb0050","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jns.2026.126097_bb0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.jns.2026.126097_bb0060","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.126097_bb0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/019131200750060023","article-title":"Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases","volume":"24","author":"Vital","year":"2000","journal-title":"Ultrastruct. Pathol."},{"issue":"4","key":"10.1016\/j.jns.2026.126097_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/mus.880120402","article-title":"Sural nerve biopsy in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"12","author":"Krendel","year":"1989","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jns.2026.126097_bb0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<474::AID-MUS8>3.0.CO;2-9","article-title":"Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy","volume":"19","author":"Schmidt","year":"1996","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1529-8027.2003.03003.x","article-title":"Pathological findings in a patient with ventilatory failure and chronic inflammatory demyelinating polyneuropathy","volume":"8","author":"Kimber","year":"2003","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"3","key":"10.1016\/j.jns.2026.126097_bb0085","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.52.3.498","article-title":"Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy","volume":"52","author":"Bouchard","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2026.126097_bb0090","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/WNL.0b013e318245d250","article-title":"CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"78","author":"Schneider-Hohendorf","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2026.126097_bb0095","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0b013e31827debad","article-title":"Recovery of the T-cell repertoire in CIDP by IV immunoglobulins","volume":"80","author":"Mausberg","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/jns.12533","article-title":"B-cell and T-cell receptor repertoire in chronic inflammatory demyelinating polyneuropathy, a prospective cohort study","volume":"28","author":"van Lieverloo","year":"2023","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"6","key":"10.1016\/j.jns.2026.126097_bb0105","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8","article-title":"Passive transfer of demyelination by serum of IgG from chronic inflammatory demyelinating polyneuropathy patients","volume":"47","author":"Yan","year":"2000","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1529-8027.2012.00372.x","article-title":"Nodal proteins are target antigens in Guillain-Barr\u00e9 syndrome","volume":"17","author":"Devaux","year":"2012","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-510X(84)90136-9","article-title":"Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G","volume":"66","author":"Heininger","year":"1984","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jns.2026.126097_bb0120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrneurol.2017.84","article-title":"Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications","volume":"13","author":"Querol","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0125","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1038\/s41598-017-14853-4","article-title":"Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"7","author":"Querol","year":"2017","journal-title":"Sci. Rep."},{"issue":"Pt 6","key":"10.1016\/j.jns.2026.126097_bb0130","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/brain\/aww062","article-title":"Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects","volume":"139","author":"Manso","year":"2016","journal-title":"Brain J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.126097_bb0135","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/brain\/awx124","article-title":"Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy","volume":"140","author":"Delmont","year":"2017","journal-title":"Brain J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2026.126097_bb0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0006-8993(87)90572-5","article-title":"Complement depletion suppresses Lewis rat experimental allergic neuritis","volume":"419","author":"Feasby","year":"1987","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.jns.2026.126097_bb0145","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/ene.14133","article-title":"Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates","volume":"27","author":"Vallat","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126097_bb0150","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0165-5728(88)90101-4","article-title":"Immune reactive C3d on the surface of myelin sheaths in neuropathy","volume":"18","author":"Hays","year":"1988","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2026.126097_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578848","article-title":"The activation of classical and\/or lectin complement pathway for the pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"412","author":"Murakami","year":"2026","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mus.24109","article-title":"Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy","volume":"50","author":"Guptill","year":"2014","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2026.126097_bb0165","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2026.126097_bb0170","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","author":"Guo","year":"2018","journal-title":"Front. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2026.126097_bb0175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2011.05.035","article-title":"Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study","volume":"308","author":"Rajabally","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.126097_bb0180","first-page":"408","article-title":"Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?","author":"Allen","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2026.126097_bb0185","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s13311-021-01108-4","article-title":"Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy","volume":"18","author":"Dalakas","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.jns.2026.126097_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000590","article-title":"Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study","volume":"6","author":"Van Schaik","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.jns.2026.126097_bb0195","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment","volume":"11","author":"Dyck","year":"1982","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.126097_bb0200","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.126097_bb0205","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","article-title":"Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP","volume":"86","author":"Nobile-Orazio","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2026.126097_bb0210","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial","volume":"9","author":"van Schaik","year":"2010","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126097_bb0215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.jns.2026.126097_bb0220","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"Pt 4","key":"10.1016\/j.jns.2026.126097_bb0225","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain J. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2026.126097_bb0230","article-title":"Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"2015","author":"Mehndiratta","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.jns.2026.126097_bb0235","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mus.28436","article-title":"Mycophenolate facilitates improvement in outcome measures in treatment resistant chronic inflammatory demyelinating polyradiculoneuropathy","volume":"72","author":"Miah","year":"2025","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2026.126097_bb0240","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","author":"RMC Trial Group","year":"2009","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.jns.2026.126097_bb0245","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP trial): a double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.jns.2026.126097_bb0250","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.35.8.1173","article-title":"Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy","volume":"35","author":"Dyck","year":"1985","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0255","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.53.1.57","article-title":"Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"53","author":"Hadden","year":"1999","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2026.126097_bb0260","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0b013e3181d1a862","article-title":"Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"74","author":"Hughes","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2026.126097_bb0265","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/brain\/awae400","article-title":"Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial","volume":"148","author":"Nobile-Orazio","year":"2025","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jns.2026.126097_bb0270","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.26804","article-title":"Rituximab in refractory chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Muley","year":"2020","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.jns.2026.126097_bb0275","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/jnnp-2023-332844","article-title":"Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies","volume":"95","author":"Doneddu","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2026.126097_bb0280","first-page":"3317","article-title":"Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport","volume":"157","author":"Leach","year":"1996","journal-title":"J. Immunol. Baltim. Md."},{"key":"10.1016\/j.jns.2026.126097_bb0285","first-page":"1","article-title":"The therapeutic age of the neonatal Fc receptor","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.jns.2026.126097_bb0290","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13","key":"10.1016\/j.jns.2026.126097_bb0295","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1073\/pnas.0600548103","article-title":"Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene","volume":"103","author":"Wani","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jns.2026.126097_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRN receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126097_bb0305","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"10.1016\/j.jns.2026.126097_bb0310","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jns.2026.126097_bb0315","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jns.2026.126097_bb0320","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex\u2013mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.jns.2026.126097_bb0325","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.immuni.2013.11.003","article-title":"Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer","volume":"39","author":"Baker","year":"2013","journal-title":"Immunity"},{"issue":"27","key":"10.1016\/j.jns.2026.126097_bb0330","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1073\/pnas.0801717105","article-title":"Dependence of antibody-mediated presentation of antigen on FcRn","volume":"105","author":"Qiao","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.jns.2026.126097_bb0335","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200455","article-title":"Unknown immunoregulatory effects of FcRn inhibition by efgartigimod in myasthenia gravis","volume":"12","author":"Tarasco","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"key":"10.1016\/j.jns.2026.126097_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863095","article-title":"FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus","volume":"13","author":"Maho-Vaillant","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jns.2026.126097_bb0345","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J. Exp. Med."},{"issue":"13","key":"10.1016\/j.jns.2026.126097_bb0350","article-title":"Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders","author":"Ward","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jns.2026.126097_bb0355","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40264-025-01549-2","article-title":"Impact of batoclimab treatment on LDL-C with and without coadministration of atorvastatin: results from a phase I randomized study in healthy participants","volume":"48","author":"Hardy","year":"2025","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.jns.2026.126097_bb0365","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/1744666X.2025.2497840","article-title":"Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases","volume":"21","author":"Gwathmey","year":"2025","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0370","doi-asserted-by":"crossref","DOI":"10.1080\/1547691X.2025.2459934","article-title":"Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys","volume":"22","author":"Binazon","year":"2025","journal-title":"J. Immunotoxicol."},{"issue":"5","key":"10.1016\/j.jns.2026.126097_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"18","key":"10.1016\/j.jns.2026.126097_bb0380","article-title":"Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study","author":"Leu","year":"2024","journal-title":"Front. Neurosci."},{"issue":"15_supplement","key":"10.1016\/j.jns.2026.126097_bb0385","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079","article-title":"RVT-1401, a novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration (P5.2-079)","volume":"92","author":"Collins","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2026.126097_bb0390","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/acn3.51946","article-title":"Subcutaneous batoclimab in generalized myasthenia gravis: results from a phase 2a trial with an open-label extension","volume":"11","author":"Nowak","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126097_bb0395","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2026.126097_bb0400","series-title":"Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential [Internet]","author":"Immunovant Inc.","year":"2023"},{"issue":"414","key":"10.1016\/j.jns.2026.126097_bb0405","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.jns.2026.126097_bb0410","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/jnnp-2023-333112","article-title":"Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study","volume":"95","author":"Querol","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2026.126097_bb0415","series-title":"Poster presented at 2024 AAN Annual Meeting, Orlando FL, USA","article-title":"Long-term safety outcomes of rozanolixizumab treatment in patients with generalized myasthenia gravis: a pooled analysis","author":"Vissing","year":"2024"},{"key":"10.1016\/j.jns.2026.126097_bb0420","series-title":"Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies [Internet]","author":"Immunovant Inc.","year":"2025"},{"issue":"468","key":"10.1016\/j.jns.2026.126097_bb0425","article-title":"Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment","author":"Levine","year":"2025","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:09:42Z","timestamp":1786219782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26003795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":84,"alternative-id":["S0022510X26003795"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126097","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FcRn inhibitors in the treatment of CIDP","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126097"}}